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Objectives
 Identify the drug–food and drug–nutrient interactions that result in enhanced positive drug
effects
 Discuss the mechanisms of positive drug–food and drug–nutrient interactions
 Identify patient-specific clinical conditions that may benefit from positive drug–food and
drug–nutrient interactions
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1. INTRODUCTION
Drug–nutrient interactions are often the result of physical and chemical
interactions between drugs and nutrients. These interactions are influenced by factors
of a physicochemical nature (e.g., pH, dissolution, disintegration, binding) or
physiological determinants (e.g., absorption, elimination, gastrointestinal transit
time, gastrointestinal secretions, splanchnic blood flow, liver enzyme inhibition or
induction) (1,2). Clinically significant negative drug–nutrient interactions may result
in therapeutic failure, drug toxicity, or nutrient deficiency. Less commonly considered
are drug–nutrient interactions that may significantly enhance drug effect, reduce
drug toxicity, or reduce gastrointestinal drug intolerance. This chapter focuses on
beneficial and clinically relevant drug–food and drug–nutrient interactions that
improve serum drug concentrations, enhance therapeutic drug effects, or reduce or
prevent severe drug toxicities (Table 1). Although data describing positive effects of
food ondrug absorption are commonly recognized, there are also examples of specific
nutrients that improve drug absorption, enhance drug effect, and reduce drug
toxicity.
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2. EFFECTS OF FOOD ON DRUG ABSORPTION
2.1. Anthelmintics
2.1.1. ALBENDAZOLE
Albendazole is a broad-spectrum anthelmintic agent effective against larval
and adult stages of trematodes and cestodes (3). Albendazole is available
commercially as oral tablets. Because of its low aqueous solubility, albendazole
is poorly absorbed from the gastrointestinal tract. However, administration
with a fatty meal enhances albendazole solubility and thereby increases its
bioavailability.
Fatty meals increase the oral bioavailability of albendazole up to fivefold as
compared with the fasting state. Maximal plasma concentrations of albendazole
sulfoxide (the primary active metabolite) were achieved in 2–5 h with albendazole
400 mg doses during treatment of patients with hydatid disease (4). In a study that
assessed the bioavailability of albendazole in six patients with hydatid disease, mean
plasma albendazole concentrations were 4.5 times higher when albendazole was
administered with breakfast as compared with fasting (5). In another study of adult
patients with onchocerciasis, plasma albendazole sulfoxide concentrations
increased fourfold when albendazole was administered with breakfast (43.1 g of
fat) instead of on an empty stomach (6). However, when albendazole was given
with 20 mL of olive oil in 100 mL of milk to four adult volunteers, plasma
albendazole sulfoxide concentrations increased 3.5-fold in one subject whereas
only small changes occurred in the other three subjects (7).
Albendazole absorption is significantly increased when taken with food.
Albendazole should be administered with fatty meals to increase its concentrations
within tissues and hydatid cysts (4). However, administration of albendazole on an
empty stomach is preferable when intraluminal effects are desired to treat suscep-
tible intestinal parasites (3,5).
2.1.2. MEBENDAZOLE
Mebendazole is a broad-spectrum anthelmintic agent that is available as oral
chewable tablets. Mebendazole is poorly absorbed from the gastrointestinal tract,
but its absorption is increased when administered with food (3). When used for the
treatment of echinococcosis, systemic bioavailability and intracystic mebendazole
concentrations are essential to achieve therapeutic effect.
Administration of mebendazole 1.5 g with a fatty meal to three healthy volun-
teers resulted in an eightfold increase in plasmamebendazole concentrations. When
administered in the fasting state, plasma mebendazole concentrations remained
<17 nmol/L in two subjects and reached 17 nmol/L in the third subject. When the
same dose was administered with a standard breakfast (2 slices of ham, 2 fried eggs,
10 g butter, jam, bread, and coffee), plasma mebendazole concentrations rose
within 2–4 h to 91 nmol/L, 112 nmol/L, and 142 nmol/L in the three subjects,
respectively (8). Mixing mebendazole with olive oil also increased the drug’s
bioavailability to a greater level than giving the tablets or suspension with a stand-
ard breakfast (9). A wide variability in mebendazole absorption was reported in
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patients treated for hydatid cysts. Although plasma mebendazole concentrations
were higher whenmebendazole was given with food, the difference was not found to
be significant (10).
When taken with food, higher plasma mebendazole concentrations are achieved.
This is a desirable effect for the treatment of hydatid cysts. Mebendazole tablets can
be chewed, swallowed whole, or crushed and mixed with food (11).
2.2. Antibiotics
2.2.1. CEFUROXIME
Cefuroxime is a broad-spectrum beta-lactam antibiotic belonging to the second-
generation cephalosporins. Cefuroxime has broad activity against susceptible bac-
teria that cause infections of the upper and lower respiratory tract, skin and soft
tissues, and the genitourinary tract (12). Cefuroxime is available as the prodrug
cefuroxime axetil in oral suspension and tablet dosage forms and as crystalline
cefuroxime for intravenous administration (13). Due to the enhanced lipid solu-
bility of the prodrug, oral cefuroxime axetil is rapidly absorbed from the gastro-
intestinal tract and is hydrolyzed to active cefuroxime once in the bloodstream
(12–14). However, the oral tablet and suspension forms of cefuroxime axetil are not
bioequivalent and cannot be used interchangeably (13). The safety and the efficacy
of oral cefuroxime tablet and suspension were established in separate clinical trials,
and the dosage forms have different therapeutic indications (12,13). Since the
cefuroxime axetil oral tablet first became available, it has been reformulated several
times due to absorption problems (14). Food (15–17) and milk (18) have been
shown to enhance cefuroxime axetil bioavailability, but the exact mechanism of this
effect remains unknown.
A randomized, crossover, open label study evaluated the effects of food and
fasting on cefuroxime bioavailability in healthy volunteers. The mean cefuroxime
absolute bioavailability during fasting was 32–35%. There was a 34% relative
increase in bioavailability when cefuroxime axetil was taken with food (area
under the plasma concentration-time curve, AUC: 50 mgh/mL) as compared to
fasting (AUC: 36.4 mgh/mL). Food also resulted in increases of the peak plasma
concentrations (Cmax: 13.9 mg/mL vs. 9.9 mg/mL) and time-to-peak concentration
(Tmax: 2.7 h vs. 2.1 h, respectively) compared to fasting. Cefuroxime elimination
half-life was not significantly changed (15). In another study, similar effects of food
on cefuroxime absorption were observed. A single 500 mg dose of cefuroxime axetil
taken with food resulted in increased absolute cefuroxime bioavailability from 36 to
52%, corresponding to a 45% relative increase. A linear correlation was also
observed between single doses of cefuroxime ranging from 125 to 1000 mg given
with food and both the AUC (r2 ¼ 0.958) and Cmax (r2 ¼ 0.943) (16).
A study evaluated the effects of food and increased gastric pH (with adminis-
tration of ranitidine and sodium bicarbonate) on cefuroxime absorption in six
healthy volunteers. When cefuroxime was administrated with food, cefuroxime
bioavailability increased despite the anticipated negative effects of a higher gastric
pH on cefuroxime absorption. Cefuroxime AUC significantly increased with food
as compared to fasting (39.8 2.9 mg h/mL vs. 23.4 2.9 mgh/mL, p< 0.05); Tmax
was significantly longer when cefuroxime was taken with food as compared to
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fasting (13.6 1.0 h vs. 7.3 0.8 h, p< 0.05); andCmax was slightly higher in the fed
state with a statistically significant difference as compared to fasting (1.5 0.1mg/L
vs. 1.4  0.152 mg/L, p < 0.05) (19).
In a study that evaluated the effects of food on cefuroxime serum concentrations
and the minimum inhibitory concentration (MIC), serum cefuroxime concentra-
tions were at or above the MIC of common respiratory pathogens for much of the
dosing interval (17). This suggests that administration of cefuroxime axetil with
food achieves adequate serum concentrations for the effective treatment of suscep-
tible organisms (12–17).
Pharmacokinetic differences exist between the cefuroxime tablet and suspension
forms to the point that they are not bioequivalent (12–20). The AUC and Cmax for
cefuroxime suspension average 91 and 71% respectively, of that for the tablet (12).
When given with meals, cefuroxime had a significantly lower AUC for oral
cefuroxime suspension as compared to the tablet (10.22 mgh/mL vs. 14.02 mgh/
mL, respectively; p¼ 0.001). Food resulted in significantly lowerCmaxwith cefuroxime
suspension as compared to the tablet (2.48 mg/mL vs. 4.04 mg/mL, respectively;
p ¼ 0.001). Despite these differences, serum cefuroxime bactericidal activities were
not affected and remained similar with both dosage forms (20). Because bacterio-
logical and clinical responses to cefuroxime axetil tablets are independent of food
ingestion, tablets may be administered without regard to meals. Pharmacokinetic,
efficacy, and safety studies of cefuroxime axetil suspension in pediatric patients were
conducted in the fed state. No kinetic data on the suspension formulation are available
when administered under fasting conditions in pediatrics (13).
In summary, cefuroxime axetil tablets and suspension are not bioequivalent and
cannot be substituted on a milligram-per-milligram basis. Oral cefuroxime axetil
tablets can be administered with or without food. Oral cefuroxime suspension
should be taken with food (13).
2.2.2. NITROFURANTOIN
Nitrofurantion is a broad-spectrum bactericidal agent that exerts its effects by
possibly interfering with bacterial carbohydrate metabolism (21,22) or cell wall
synthesis (23). Nitrofurantoin is used for the treatment of uncomplicated urinary
tract infections caused by susceptible microorganisms. Nitrofurantoin is available
in different oral formulations including a combination formulation of nitrofurantoin
monohydrate (75%of the drug) andmacrocrystals (25%of the drug) in oral capsules
(Macrobid1), nitrofurantoin macrocrystalline oral capsules (Macrodantin1), and
microcrystalline oral suspension (Furadantin1) (24–26). A tablet formulation of
nitrofurantoin was previously manufactured but is no longer available.
Oral nitrofurantoin is absorbed in the small intestines. Because serum nitro-
furantoin concentrations are usually low or undetectable in patients with normal
renal function (21,27,28), urinary nitrofurantoin levels are typically used to assess
nitrofurantoin absorption (29). Macrocrystalline nitrofurantoin has a slower dis-
solution and absorption rate than nitrofurantoin monohydrate. Food, however,
increases the bioavailability of nitrofurantoin by about 40% (24) and substantially
increases the duration of therapeutic nitrofurantoin urine concentrations (21).
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The effects of food on nitrofurantoin absorption in macrocrystalline and micro-
crystalline tablets were evaluated in a study of four healthy volunteers. Nitrofuran-
toin 100 mg single oral dose was administered either following an 8-h overnight fast
or immediately after breakfast. Serial urinary specimens were collected to measure
nitrofurantoin urine concentrations. Study results showed that food delayed nitro-
furantoin absorption in the macrocrystalline form but did not have a significant
effect on the rate of absorption of the microcrystalline form. Food also resulted in
increased maximum urine excretion rate of macrocrystalline nitrofurantoin but did
not have a significant effect on the rate of excretion of the microcrystalline form.
Compared to fasting, food increased nitrofurantoin bioavailability by an average of
30 and 80% of the microcrystalline and macrocrystalline forms, respectively (30).
Another study compared the effects of food on the oral bioavailability of nitro-
furantoin in three different microcrystalline tablets, a macrocrystalline capsule, and
an aqueous microcrystalline suspension. The percent of a single 100 mg oral dose
recovered in the urine was significantly greater when administered with food as
compared to the fasting state for the microcrystalline tablets (p < 0.05) and the
macrocrystalline capsule (p< 0.05). Food increased the bioavailability of the tablets
and the macrocrystalline capsule by 23–40 and 85%, respectively. Although the
bioavailability of the microcrystalline suspension was also increased with food, it
was not statistically significant. Compared to fasting, food also significantly
increased the mean duration of therapeutic urinary concentrations of nitrofuran-
toin macrocrystalline capsules (p < 0.05). Food also increased the duration of
therapeutic urinary concentrations of the microcrystalline suspension, but the
difference was not statistically significant compared to the fasted state. Nitro-
furantoin administration with food improved the uniformity of nitrofurantoin
absorption and decreased the coefficients of variation. It was hypothesized that by
decreasing the rate of gastric emptying, food increased nitrofurantoin residence in the
stomach thereby increasing drug dissolution that makes nitrofurantoin more readily
absorbed in the small intestines (31).
In summary, food delays nitrofurantoin delivery to the intestines thereby increas-
ing its absorption and reducing its peak plasma concentrations (26,31). Nitro-
furantoin macrocrystals are more slowly absorbed than the microcrystals (29,32).
Therefore, the macrocrystals are better tolerated and are associated with less nausea
and vomiting (33–35). Nitrofurantoin should be administeredwith food to enhance
its absorption, increase the duration of nitrofurantoin urinary concentrations, and
improve gastrointestinal tolerance (24).
2.3. Antifungals
2.3.1. GRISEOFULVIN
Griseofulvin is an oral antifungal agent used for the treatment of tinea infections.
Because of its low aqueous solubility, griseofulvin absorption is slow, irregular, and
incomplete, especially when taken on an empty stomach (36). However, griseoful-
vin absorption increases twofold when taken with fatty meals (37). Food increases
griseofulvin absorption by increasing its disintegration and de-aggregation (38).
In a study of 12 adult volunteers who each received a single dose of griseofulvin
500 mg tablet, there was a significant increase in griseofulvin bioavailability of
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70 and 120% when taken with a low-fat (29.3% calories from fat) and high-fat
(52.4% calories from fat) meals, respectively, compared to fasting (p < 0.01) (39).
However, one older study, using urinary excretion data, concluded that fatty meals
increase the rate but not the extent of griseofulvin absorption, and that griseofulvin
follows a circadian rhythm of absorption regardless of dietary fat content (40).
Griseofulvin absorption also varies with the dosage form used. A crossover study
of four healthy volunteers compared the absorption of two different dosage forms
consisting ofmicrosize and ultramicrosize griseofulvin tablets takenwith or without
food. When taken on an empty stomach, griseofulvin Cmax of the ultramicrosize
formulation was about 70% of the microsize formulation. When taken with food,
griseofulvin Cmax was 136% of the microsize formulation and about twice the Cmax
for the ultramicrosize formulation. The rate and the extent of griseofulvin bioavail-
ability were similar for both formulations when taken with food (38).
In summary, optimal plasma griseofulvin concentrations are attained when
griseofulvin is administered with a high-fat meal. Taking griseofulvin with meals
maximizes its absorption and enhances therapeutic drug effect.
2.3.2. ITRACONAZOLE
Itraconazole is a triazole antifungal used for treating superficial and systemic
fungal infections. Itraconazole is available as oral solution and capsule formula-
tions. Each oral itraconazole dosage form has specific indications (41). Injectable
itraconazole has been discontinued by the manufacturer for sales and distribution in
the United States. Itraconazole is a highly lipophilic, extremely weak base that is
almost insoluble in water and requires an acidic medium for optimal oral absorption
(42,43). The bioavailability of oral itraconazole also depends on the dosage form
and the presence or absence of food. Whereas food enhances itraconazole capsule
dissolution and absorption (44,45), oral itraconazole solution is already in the
dissolved form and is better absorbed when taken on empty stomach (46).
In one study, the bioavailability of itraconazole capsules increased from 40%
with fasting to 102% when administered with meals (44). In another study of 27
healthy volunteers, a single dose of itraconazole 200 mg capsule was administered
with or without food. Pharmacokinetic parameters were analyzed for itraconazole
and its active metabolite hydroxyitraconazole. The AUC for itraconazole and
hydroxyitraconazole was higher when the drug was administered with food (3423
 1154 ng h/mL and 7978  2648 ngh/mL, respectively) as compared to fasting
(2094  905 ngh/mL and 5191  2489 ngh/mL, respectively). The Cmax for
itraconazole with fasting was 59% of that with food (140  65 ng/mL and 239 
85 ng/mL, respectively), andCmax for hydroxyitraconazole with fasting was 72% of
that with food (286  101 ng/mL and 397  103 ng/mL, respectively) (41).
The absorption of oral itraconazole capsules is decreased with increasing gastric
pH such as in patients receiving gastric acid inhibitors (antacids, H2-receptor antag-
onists, proton pump inhibitors). In patients with hypochlorhydria, coadministration
of oral itraconazole capsules with an acidic beverage (e.g., cola) increased itraconazole
bioavailability (47,48). Following the administration of a single 100 mg dose of
itraconazole capsules with 325 mL of water or an acidic cola beverage (pH ¼ 2.5),
the itraconazole AUC was significantly higher with cola (2.02  1.41 mgh/mL) than
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with water (1.12 1.09 mgh/mL) (p< 0.05). Itraconazole Cmax was also significantly
higher with cola than with water (0.31  0.18 mg/mL vs. 0.14  0.9 mg/mL, respect-
ively; p< 0.05), and Tmax was significantly longer (3.38  0.79 h vs. 2.56  0.62 h;
p < 0.05) (48).
In contrast to itraconazole capsules, itraconazole oral solution does not require
food or an acidic medium to increase its absorption. Significantly higher itraconazole
and hydroxyitraconazole AUC and Cmax and shorter Tmax occur when itraconazole
oral solution is taken on an empty stomach rather than with food (42). Following
administration of oral itraconazole solution at a dose of 200mg/day, respective mean
itraconazole and hydroxyitraconazole concentrations were 43 and 38% higher when
the drug was taken with food as compared to fasting (46). The AUC with a single
100 mg dose of itraconazole oral solution was significantly higher when administered
during fasting (2379 1353 ngh/mL) as compared to the fed state (1713 741 ngh/
mL). Cmax was also significantly higher in the fasting state as compared to the fed
state (349  239 ng/mL vs. 147  74 ng/mL; p ¼ 0.006). Additionally, Tmax was
significantly shorter during fasting as compared to the fed state (1.7 0.5 h vs. 3.8
1.4 h; p ¼ 0.0001) (42).
In summary, oral itraconazole capsules should be taken with a full meal for
maximal absorption. However, oral itraconazole solution is better absorbed when
taken on empty stomach at least 2 h before or 2 h after a meal. Oral itraconazole
solution provides an alternative to itraconazole capsules in patients who have
difficulty swallowing the capsule or in those whose oral intake is restricted
(41,45). The optimal serum itraconazole and hydroxyitraconazole concentrations
are not known; however itraconazole oral solution is associated with higher serum
drug concentrations compared to oral capsules (49). Administration of itraconazole
with cola enhances itraconazole capsule absorption in patients receiving acid sup-
pression therapy (47). Patients receiving medications that alter gastric pH should
take itraconazole oral capsules with a cola beverage.
2.3.3. POSACONAZOLE
Posaconazole is a triazole antifungal agent that works by blocking the synthesis of
ergosterol, one of the key compounds in the fungal cell membrane. Posaconazole is
FDA labeled for the prophylaxis of invasive Aspergillus or Candida infections in
patients who are at risk of developing systemic infections due to an immunocom-
promised state (50). Posaconazole is insoluble in water and is commercially available
as a suspension for oral administration. It is well absorbed from the gastrointestinal
tract with a proportional increase in AUC and Cmaxwith increasing doses up to
800 mg daily. Steady-state plasma posaconazole concentrations are reached after
7–10 days of therapy with a Tmax ranging from 5.8 to 8.8 h (51).
A study evaluated the difference in absorption of posaconazole oral suspension
and tablet formulations and the effect of food and its fat content on posaconazole
bioavailability (52). In this randomized, open label, four-way crossover study, 20
healthy male volunteers received posaconazole 200 mg oral tablets administered
with a high-fat breakfast (841 calories, 52% fat), or posaconazole 200 mg oral
suspension administered with a high-fat breakfast, low-fat breakfast (461 calories,
0% fat), or after a 10-h fast. Absorption was significantly better with the oral
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suspension compared to the tablets with a 37% increase in AUC (p¼ 0.001) and 23%
increase inCmax(p¼ 0.004). In addition, theAUCandCmax of the oral suspensionwere
4 times greater with the high-fat meal compared with the fasted state (p < 0.001).
Administration with the low-fat meal also increased posaconazole absorption
(2.6 times) and Cmax (3 times) compared to the fasted state (p < 0.001). Pharmaco-
kinetic profiles were similar between the high-fat and nonfat meals, suggesting that
posaconazole should be administered with meals regardless of fat content and that the
suspension should be used over the tablets to enhance absorption. A related study
found that concomitant administration of antacids with posaconazole had no signifi-
cant effect on posaconazole bioavailability under fasting or nonfasting conditions (53).
Patients who receive posaconazole are often severely ill and may have difficulty
eating. It would not be uncommon for these patients to receive their nutritional
needs through enteral tube feedings. For this reason, a study evaluated the effect
of a nutritional supplement (Boost Plus1, Novartis Nutrition Corp.) on the
bioavailability of posaconazole (54). In a randomized, crossover study, 20
healthy subjects received 400 mg of posaconazole oral suspension either after an
overnight fast or with 8 ounces of the nutritional supplement (360 calories, 34%
fat). Coadministration of posaconazole with the nutritional supplement resulted
in a threefold increase in posaconazole Cmax and a 2.6-fold increase in AUC
compared to the fasted state. There was no difference in posaconazole Tmax or
half-life between the two groups.
In summary, posaconazole is a highly lipophilic compound for which adminis-
tration with food results in a clinically significant increase in bioavailability.
Posaconazole should always be administered with food regardless of fat content,
or with a nutritional supplement to ensure adequate plasma posaconazole concen-
trations. If the patient cannot meet these feeding requirements, the manufacturer of
posaconazole recommends that another antifungal agent be considered or that the
patient be closely monitored for breakthrough fungal infections (50).
2.4. Antiprotozoals
2.4.1. ATOVAQUONE
Atovaquone is an antiprotozoal agent available as an oral suspension. It is used
as a second-line agent for the treatment or prophylaxis ofmild tomoderatePneumo-
cystis carinii pneumonia in patients who are intolerant of trimethoprim-sulfame-
thoxazole (cotrimoxazole). Atovaquone is highly lipophilic with a low aqueous
solubilitymaking it slowly and irregularly absorbed on an empty stomach.Atovaquone
bioavailability is enhanced when taken with a fatty meal. The previously marketed
atovaquone tablet resulted in irregular absorption and subtherapeutic plasma concen-
trations. As such, manufacturing of atovaquone tablets (Mepron1) was discontinued
once the suspension became commercially available. Atovaquone suspension exhibits
double the bioavailability compared to the tablet (55), resulting in increased
atovaquone AUC and Cmax (56).
In a prospective, open label, crossover study of 10 healthy volunteers, the bio-
availability of atovaquone (single 750 mg dose of suspension) was enhanced when
administered following breakfast (fat content 21 g) or with an oral liquid nutrition
supplement (Sustacal Plus1, Mead Johnson Nutritionals: fat content 28 g). The
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AUC of atovaquone following breakfast (103.8 mg h/mL) and Sustacal Plus1
(118.8 mg h/mL) was significantly higher when compared to administration under
fasting conditions (43.4 mg h/mL) (p< 0.0001). This corresponds to amean increase
in atovaquone bioavailability by 502 and 505% following breakfast and Sustacal
Plus1, respectively (57).
Two studies investigated the effect of food on the pharmacokinetics of
atovaquone suspension in patients infected with HIV (58,59). In an open
label, dose escalation study including 22 HIV-infected patients, administration
of atovaquone with breakfast (fat content 23 g) increased average atovaquone
steady-state plasma concentrations by 1.3- to 1.7-fold as compared to fasting
(58). Similarly, a single- and multiple-dose pharmacokinetic study in HIV-
infected patients showed food to increase atovaquone bioavailability by 1.4-fold.
However, an increased incidence of rash was observed when higher plasma
atovaquone concentrations were achieved with the 1000 mg twice daily dose
taken with food (59).
In summary, the rate and the extent of atovaquone absorption are significantly
increased when taken with food, especially fatty meals. As such, atovaquone should
be administered with meals to increase its absorption and improve its therapeutic
effects (55).
2.4.2. NITAZOXANIDE
Nitazoxanide is an antiprotozoal agent that is FDA labeled for the treatment of
diarrhea associated with cryptosporidiosis (caused byCryptosporidium parvum) and
giardiasis (caused by Giardia lamblia). Nitazoxanide is practically insoluble in
water. It is available in oral tablet (500 mg) and suspension (100 mg/5 mL) for-
mulations which are not bioequivalent. The relative bioavailability of nitazoxanide
suspension is 70% compared to the tablet. Although specific data on the bioavail-
ability of nitazoxanide are lacking, nitazoxanide is metabolized in the gut wall, liver,
and plasma. Nitazoxanide is rapidly converted to the active metabolite tizoxanide
that is ultimately excreted in the urine, bile, and feces. About 67% of the parent
nitazoxanide is excreted in the feces (60).
Food significantly increases the absorption of nitazoxanide. Administration of
nitazoxanide tablets with food resulted in a twofold increase in the AUC of
tizoxanide and the metabolite tizoxanide glucuronide, and a 50% increase in
Cmax. Administration of nitazoxanide oral suspension with food resulted in a
45–50% increase in AUC of tizoxanide and tizoxanide glucuronide and an
increase in Cmax by up to 10% (60). A study in 32 healthy volunteers evaluated
the absorption of nitazoxanide following the administration of a single oral
nitazoxanide dose of 1 g, 2 g, 3 g, or 4 g first under fasting conditions, and a
week later with breakfast. Study results showed that food approximately doubled
the plasma concentrations of tizoxanide and tizoxanide glucuronide irrespective
of the administered dose (61).
In clinical trials, nitazoxanide was administered with food that substantially
increased drug absorption. Therefore, nitazoxanide oral tablets and suspension
should be taken with food.
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2.5. Antiretrovirals
2.5.1. ATAZANAVIR
Atazanavir is an HIV-1 protease inhibitor that is indicated for the treatment
of HIV-1 infection when used in combination with other antiretroviral agents.
Atazanavir selectively inhibits virus-specific processing of HIV-1 infected cells,
thereby preventing the formation of mature virons (62).
Pharmacokinetic data supporting the effect of food on the absorption of atazanavir
capsules are limited to information found in the product labeling, but are worthy of
mention. Atazanavir is rapidly absorbed after oral administration. Steady-state
plasma atazanavir concentrations are achieved after 4–8 days of continuous therapy.
Absorption is significantly increased when atazanavir is administered with food as
compared to the fasting state. Thismay in part be due to improved atazanavir solubility
with decreasing pH. When a single dose of atazanavir 400 mg was administered with a
light meal, the AUC of atazanavir increased by 70%, and Cmax increased by 57%
relative to fasting. When administered with a high-fat meal, the AUC of atazanavir
increased by 35%with no change inCmax relative to the fasting state. In both cases (light
meal or high-fat meal), there was a decrease in the coefficient of variation for AUC and
Cmax by approximately one-half compared to the fasting state (62).
These data suggest that administration of atazanavir with food increases its
bioavailability and reduces pharmacokinetic variability. Therefore, it is recom-
mended that atazanavir be taken with food to enhance its absorption (62).
2.5.2. DARUNAVIR
Darunavir ethanolate (Prezista1), a protease inhibitor antiretroviral agent used
for treatment ofHIV-1 infection, is marketed as 300mg oral tablets. The usual adult
darunavir dose is 600 mg (two tablets) twice daily taken together with ritonavir
100 mg. Ritonavir, another anti-HIV protease inhibitor, is coadministered at a low
dose with darunavir because it inhibits darunavir metabolism through the CYP3A4
isoenzyme and increases its plasma concentrations. Ritonavir increases the absolute
systemic bioavailability of darunavir from 37 to 82% (63).
Food increases the bioavailability of darunavir. Regardless of the type of meal
(range 240 kcal with 12 g fat to 928 kcal with 56 g fat), taking darunavir with food
along with ritonavir increased the AUC andCmax of darunavir by about 30% (63).
An open label, randomized, crossover study evaluated the effects of different meal
types on the pharmacokinetic profile of darunavir in healthy adult volunteers who
were given the darunavir/ritonavir combination. Darunavir was taken after a
period of fasting for at least 10 h, immediately following a standard breakfast
(533 kcal, 21 g fat, 67 g carbohydrate, 19 g protein), following a high-fat breakfast
(928 kcal, 56 g fat, 65 g carbohydrate, 41 g protein), after a protein-rich nutritional
drink (250 kcal, 8.4 g fat, 33.4 g carbohydrate, 10.5 g protein), or after coffee with
croissant (240 kcal, 12 g fat, 28 g carbohydrate, 5 g protein). Study results showed
that the AUC and Cmax for darunavir were 30% lower under fasting conditions
compared to when darunavir was taken with a standard breakfast. There were no
significant differences in the AUC and Cmax for darunavir when taken with the
different types of meals (64).
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In summary, darunavir should only be used in combination with ritonavir. Food
increases darunavir absorption regardless of the meal composition. Therefore, the
combination of darunavir/ritonavir should be consistently taken with food, in order
to achieve optimal therapeutic drug effects (63).
2.5.3. LOPINAVIR
Lopinavir is a protease inhibitor antiretroviral agent used for the treatment of
HIV-1 infection. It is only marketed in a co-formulation with ritonavir, a structur-
ally related protease inhibitor. Ritonavir inhibits the principal isoenzyme CYP3A4
that metabolizes lopinavir; it is, therefore, combined with a low lopinavir dose to
decrease lopinavir metabolism and increase its plasma concentrations, thereby
enhancing its anti-HIV activity (65).The lopinavir/ritonavir co-formulation is
marketed as Kaletra1and is available as oral tablets (lopinavir 200 mg/ritonavir
50mg) and oral solution (lopinavir 80mg/ritonavir 20mg per 1mL) (66). Themain
antiviral activity of Kaletra1is due to lopinavir.
Originally, the lopinavir/ritonavir formulation was available in oral soft gelatin
capsules that required a daily dosing of six capsules taken with food. Because of
patient compliance issues and storage requirements, the lopinavir/ritonavir oral
capsules were replaced with a tablet formulation that was manufactured using a
special melt extrusion technology that limits the excipient mass. The tablet formu-
lation has significantly improved bioavailability under various meal conditions and
is bioequivalent to the oral soft gelatin capsule when taken after a moderate fat
meal. The tablet formulation also reduced the number of lopinavir/ritonavir doses
to four tablets daily that can be easily stored at room temperature (66,67). The
absorption of Kaletra1oral tablets is not significantly affected by the presence of
moderate or high-fat meals, but there is less variability and more consistent lopi-
navir and ritonavir absorption when administered with food compared to the fasted
state (67). However, the absorption of lopinavir in Kaletra1oral solution is sub-
stantially increased when taken with food. Compared to fasting, administration of
Kaletra1oral solution with a moderate fat meal (500–682 kcal, 23–25% fat)
increased lopinavir AUC by 80% and Cmax by 54%. Taking Kaletra
1oral solution
with a high-fat meal (872 kcal, 56% fat) further increased lopinavir AUC by 130%
and Cmax by 56%, relative to fasting (66).
Because the bioavailability of lopinavir oral solution is significantly increased
when taken with moderate to high fat containing meals, Kaletra1 oral solution
must be taken with food to improve therapeutic drug effects. Kaletra1 oral tablets
can be taken with or without food.
2.5.4. NELFINAVIR
Nelfinavir is a protease inhibitor antiretroviral agent used for treatment of HIV-1
infection.Nelfinavir is available as oral tablet (250mg, 625mg) and powder (50mg/g)
formulations that have similar bioavailability. Food increases nelfinavir absorp-
tion and decreases nelfinavir pharmacokinetic variability compared to the fasting
state (68).
A study in healthy volunteers evaluated the pharmacokinetics of a single nelfinavir
dose of 1250 mg (5  250 mg tablets) taken under fasting conditions or with
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three different meals. Study results showed that nelfinavir AUC, Cmax, and
Tmax increased with higher caloric and fat intake. Compared to the fasting
state, a low calorie and fat meal (125 kcal, 20% fat) caused an increase in the
AUC and Cmax of nelfinavir by 2.2- and 2-fold, respectively. Further increases
in nelfinavir bioavailability occurred with a meal that provided higher calories
(500 kcal, 20% fat) leading to a 3.1-fold increase in AUC and 2.3-fold increase
in Cmax. A meal with even higher calories and fat content (1000 kcal, 50% fat)
was associated with a higher 5.2-fold increase in AUC and 3.3-fold increase in
Cmax. Similar pharmacokinetic results on nelfinavir absorption were obtained
from another study in healthy volunteers that evaluated the effects of low
(20%) vs. high (50%) fat meals with similar calorie intake (500 kcal) on (68).
Although the effect of food on the pharmacokinetics of the 625 mg nelfinavir
tablet has not been separately evaluated, a crossover study that compared the effects
of food (standard breakfast at 820 kcal) on a single dose administration of nelfinavir
1250 mg (5  250 mg tablets vs. 2  625 mg tablets) showed that compared to
fasting, food caused a six- and eightfold increase in nelfinavir absorption for the
250 mg and 625 mg tablet, respectively (69).
In summary, nelfinavir bioavailability is higher when the drug is taken with high
calorie or high-fat meals. For optimal absorption and enhanced therapeutic effects,
nelfinavir should be taken with meals.
2.5.5. SAQUINAVIR
Saquinavir is an antiretroviral agent used for treatment of HIV-1 infection. It is
available in oral capsules as saquinavir mesylate (Invirase1) and in soft capsules as
saquinavir (Fortovase1). The two dosage forms are not bioequivalent and cannot
be used interchangeably. Fortovase1 has better bioavailability as compared to
Invirase1. Following administration of single 600 mg doses of saquinavir, the
relative bioavailability of Fortovase1 was 331% as compared to Invirase1.
Food, however, substantially increases saquinavir absorption with either dosage
form (70,71). Administration of saquinavir with food was reported to increase
saquinavir bioavailability by 1800% (72).
In a study of six healthy volunteers who received saquinavir in a single 600 mg
dose, a 6.7-fold increase in AUC was reported when saquinavir was administered
with food as compared to fasting. Mean 24-h saquinavir AUC increased from
24 ngh/mL with fasting to 161 ng h/mL following breakfast (1006 kcal, 57 g fat,
60 g carbohydrate, 48 g protein). The 24-h AUC and Cmax were on average twofold
higher following a higher calorie and fat meal (943 kcal, 54 g fat) than a lower
calorie and fat meal (355 kcal, 8 g fat) (70). In another study of 12 healthy
volunteers who received a single dose of Fortovase1 800 mg, the mean 12-h AUC
increased from 167 ng h/mL with fasting to 1120 ngh/mL when saquinavir was
taken with breakfast (1006 kcal, 57 g fat, 60 g carbohydrate, 48 g protein) (71).
In summary, food increases saquinavir bioavailability by increasing drug dissol-
ution and disintegration (73). As such, Fortovase1 and Invirase1should be taken
with food or within 2 h after a meal (70,71). Due to its improved absorption,
Fortovase1 should be used as the saquinavir formulation of choice in an
antiretroviral regimen.
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2.6. Fenofibrate
Fenofibrate is a fibric acid derivative prodrug that is rapidly hydrolyzed to its
major pharmacologically active metabolite, fenofibric acid. Fenofibrate reduces
serum total cholesterol, low-density lipoprotein cholesterol (LDL), very low-density
lipoprotein cholesterol (VLDL), and triglycerides, and increases high-density
lipoprotein cholesterol (HDL) in patients with dyslipidemia. Fenofibrate also
increases urinary uric acid excretion via a different mechanism, hence its off-label
use in the treatment of hyperuricemia and gout (74,75). The FDA-labeled indication
of fenofibrate is for the treatment of hypercholesterolemia, hypertriglyceridemia, and
mixed dyslipidemia (types IV and V) in adjunct to a low-fat diet (76).
Fenofibrate is well absorbed from the gastrointestinal tract with Cmax attained
6–8 h after oral administration. Fenofibrate is a neutral lipophilic compound that is
practically insoluble in aqueous solution for injection, thus the lack of data on the
drug’s absolute bioavailability. The variable bioavailability and dissolution prob-
lems of fenofibrate have led to manufacturing innovations in oral fenofibrate
formulations. Fenofibrate is available in various tablet and capsule formulations
that have different bioavailability profiles and are not bioequivalent on amilligram-
for-milligram basis. The bioavailability of the original non-micronized tablet was
improved by micronization, conferring about a 30% increase in bioavailability.
Fenofibrate capsules contain micronized fenofibrate particles that disperse and
aggregate randomly to excipients. With the fenofibrate microcoated micronized
tablet formulation, fenofibrate is coated directly into an inert excipient core which
improved its in vitro dissolution by 46% owing to it its higher bioavailability over
the non-microcoated micronized capsules. Plasma fenofibric acid concentrations
that are achieved following administration of the 54 mg or 160 mg microcoated
micronized tablets are equivalent under fed conditions to those achieved with the
67 mg or 200 mg micronized capsules, respectively. The extent of absorption of
fenofibrate micronized capsules or micronized microcoated tablets is increased by
about 35% under fed conditions compared to fasting (74,77).
Commercially available fenofibrate products can be classified based on their
formulation and whether they should be taken with or without regards to meals.
Fenofibrate formulations that should be taken with food include micronized cap-
sules (Lofibra1 67 mg, 134 mg, 200 mg), microcoated micronized tablets (Lofibra1
54 mg, 160 mg), and CIP-fenofibrate hard gelatin capsules (Lipofen1 50 mg,
100 mg, 150 mg) (78–80). Fenofibrate formulations that can be taken with or
without meals include nanoparticle tablets (Tricor1 48 mg, 145 mg), Insoluble
Drug Delivery1-Microparticle (IDD-P) tablets (Triglide1 50 mg, 160 mg), and
micronized capsules (Antara1 43 mg, 130 mg) (76,81,82).
The CIP-fenofibrate formulation (Lipofen1) is a newly developed drug delivery
technology (Lidose) that increased fenofibrate bioavailability by about 25% com-
pared to the micronized form. The CIP-fenofibrate 150 mg capsule is bioequivalent
to 160 mg micronized microcoated tablet (Tricor1) under low- and high-fat-fed
conditions. When compared to fasting conditions, the extent of Lipofen1absorp-
tion increased by about 25% when taken with a low-fat meal and by 58% with a
high-fat meal (80). Similarly, the nanoparticle technology used in the reformula-
tion of Tricor1 allowed faster drug dissolution that improved its absorption and
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allowed the drug to be taken with or without food. On the other hand, the
formulation of the IDD-P tablets uses a technology of preparing fenofibrate micro-
particles that are stabilized with phospholipid-surface-modifying agents to prevent
the re-aggregation of microparticles. This preserves the expanded drug surface area
of microparticles and increases its dissolution for better absorption. Single-dose
pharmacokinetic studies of the fenofibrate IDD-P formulation in healthy adults
showed similar AUC for fenofibrate under fed or fasting conditions (83). Although
the micronized capsules in Antara1 are better absorbed with a high-fat meal, the
package insert states that Antara1 capsules may be taken without regard to meals.
When Antara1 was administered with a high-fat meal, there was a 26% increase of
the fenofibric acid AUC and a 108% increase inCmax compared to the fasting state.
However, the AUC of fenofibric acid was unaffected when Antara1was taken with
a low-fat meal or under fasting conditions. Tmax was also unaffected in the presence
of a low-fat meal. Although Antara1 absorption was increased when taken with a
fat-rich meal, the approval of Antara1 to be administered without regard to meals
was based on data from clinical studies that showed comparable outcomes on serum
triglycerides and cholesterol concentrations when Antara1 130 mg was taken once
daily with or between meals (82). A study of an investigational sustained-release
fenofibrate 250 mg capsule showed a significant increase in AUC (3.34-fold) and
Cmax (3.82-fold) when taken with a high-fat meal compared to fasting (p < 0.01).
There was also a significant increase in AUC (2.45-fold) and Cmax (2.89-fold) when
the same formulation was given with a standard breakfast compared to fasting (p<
0.01) (84).
In summary, many different fenofibrate oral formulations are commercially
available and they are not bioequivalent. The difference in bioequivalence should
be considered when a patient is switched from one fenofibrate formulation to
another. Lofibra1 and Lipofen1 should be taken withmeals to improve absorption
and optimize therapeutic effects. Tricor1, Triglide1, and Antara1 can be taken
with or without food.
2.7. Isotretinoin
Isotretinoin is a synthetic analog of vitamin A that is available in oral capsules
and used for the treatment of cystic acne. Isotretinoin is a highly lipophilic drugwith
maximal isotretinoin absorption achieved when administered with a fatty meal
(85).
The effects of food and fasting on isotretinoin bioavailability were evaluated in a
randomized, crossover study of 20 healthy, male volunteers. Isotretinoin 80 mg was
administered either during a complete fast, 1 h before a standard breakfast, with a
standard breakfast, or 1 h after a standard breakfast. Each treatment was separated
by a washout period. Study results showed that isotretinoin bioavailability
increased by about 1.5- to 2-fold when isotretinoin was administered 1 h before,
with, or 1 h after breakfast, as compared to fasting. Mean isotretinoin Cmax
increased 1.6- to 2.4-fold in the presence of food. Tmax was slightly delayed by
0.8–1.6 h. The investigators related the positive effects of food on isotretinoin
absorption to the increased bile flow that enhances isotretinoin solubility (86).
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In summary, isotretinoin bioavailability is increased when taken with food.
Consistent intake of isotretinoin with meals is recommended in order to optimize
isotretinoin clinical effects.
2.8. Mesalamine/Olsalazine
Mesalamine (5-aminosalicylic acid) is an oral agent indicated for the treatment of
chronic inflammatory bowel disease. The exact mechanism of action of mesalamine
is unknown, but may be due to its local effects that decrease colonic inflammation
by blocking the cyclooxygenase enzyme and inhibiting prostaglandin production in
the colonic mucosa. Several different formulations of mesalamine are available on
the market. Delayed-release tablets (Lialda1, Asacol1) and controlled-release
capsules (Pentasa1) are minimally absorbed (20–30%). In addition, the delayed-
release tablets are coated with an acrylic-based resin that only dissolves at a pH of 7
or higher, releasing mesalamine in the terminal ileum. When the delayed-release
tablets are given with a high-fat meal, target exposure and absorption are delayed,
and there is an increase in systemic exposure to mesalamine (91% increase in Cmax
and 16% increase in AUC) (87). Despite enhanced absorption, the effects of
mesalamine are believed to be due to its local effects in the colonic mucosa and
not due to its systemic concentration.
Olsalazine (Dipentum1) is a prodrug containing two azo-bound molecules
of mesalamine that is cleaved by bacteria in the colon to form mesalamine
(5-aminosalicylic acid). Olsalazine is used for the maintenance of remission of
ulcerative colitis in patients who are intolerant to sulfasalazine. The oral bio-
availability of the olsalazine is limited at<3%. Oral absorption of 5-aminosalicylic
acid is also very slow, which leaves high local therapeutic drug concentrations in the
colon. Of a 1 g dose of olsalazine, more than 0.9 g of 5-aminosalicylic acid reaches
the colon where it exerts its effects (88). Food does not affect the bioavailability of
olsalazine or 5-aminosalicylic acid (89). However, because the efficacy of olsalazine
is dependent on the colonic concentration of 5-aminosalicylic acid and is independ-
ent of serum drug concentrations, taking olsalazine with food increases drug
efficacy by prolonging the presence of 5-aminosalicylic acid in the gut (88).
Because the pharmacologic action of mesalamine and olsalazine depends on the
local effects of 5-aminosalicylic acid, they should be taken with food to maximize
local colonic effects in patients with ulcerative colitis (87,88).
2.9. Misoprostol
Misoprostol is a prostaglandin E1 analog that is primarily used for preventing
gastric ulceration in patients treated with nonsteroidal antiinflammatory drugs
(NSAIDs). Misoprostol is available as oral tablets. Gastrointestinal side effects
such as diarrhea and abdominal pain are common with misoprostol therapy.
Diarrhea is dose-related andmay sometimes require discontinuation of misoprostol
therapy. The incidence of diarrhea with misoprostol 800 mg/day in patients treated
with NSAIDs ranges between 14 and 40%. Administration of misoprostol after
meals slows the rate of misoprostol absorption and thus reduces the frequency of
diarrhea (90).
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In a randomized, open label, crossover study of 12 healthy volunteers, misoprostol
absorption was studied when taken with a high-fat meal or during fasting. Study
results showed that food decreases the rate of misoprostol absorption without sig-
nificantly affecting the amount or extent of misoprostol absorption. Food signifi-
cantly increased misoprostol Tmax compared to fasting (64  79 min vs. 14  8 min;
p< 0.05). Food, however, decreased misoprostol Cmax (303 176 pg/mL) compared
to fasting (811 317 pg/mL) (p < 0.05). Because achieving a rapid, high Cmax of the
active misoprostol metabolite (misoprostol acid) may result in increased side effects
(diarrhea, abdominal pain), these effects can beminimized whenmisoprostol is taken
with food (91).
The effects of misoprostol on bowel motility were evaluated in a double-blind,
crossover study of 12 healthy volunteers. Study results showed that oral-to-cecal
transit time (measured by H2 breath test following lactulose administration) was
shortened by 57 and 18% when misoprostol was administered before and after
meals, respectively. The mean oral-to-cecal transit time was significantly shorter
when misoprostol 400 mg was taken before meals compared to after meals
(p< 0.001) and to placebo (p< 0.001). Although other parameters such as stool
frequency, fecal fat and bile acids, and fecal weight showed differences between
treatments, these differences were not found to be significant (92).
In summary, administration of misoprostol before or after meals decreases the
Cmax of the active metabolite misoprostol acid without affecting misoprostol bio-
availability (91). Misoprostol should then be taken with food to reduce the inci-
dence of diarrhea (90).
3. EFFECTS OF SPECIFIC NUTRIENTS ON DRUG ABSORPTION
3.1. Ascorbic Acid and Iron
Iron deficiency anemia can affect all age groups, especially children and women
of childbearing age. There are two forms of iron found in the diet – heme iron from
meat and non-heme iron from cereals, fruits, and vegetables. Heme iron accounts
for about 10–15% of iron intake when consuming a meat-rich diet whereas most of
the remaining dietary iron is in the non-heme form. Factors that increase (e.g.,
ascorbic acid) or decrease (e.g., phytates) non-heme iron absorption do not, how-
ever, affect heme iron absorption (93). Ferrous iron (Fe2+) is better absorbed than
ferric iron (Fe3+). Most dietary iron is in the ferric state, but factors such as gastric
acidity, dietary ascorbic acid, and other reducing substances convert ferric iron to
ferrous iron.When considering oral iron supplements, the amount of iron absorbed
depends on the type of iron salt used (sulfate vs. fumarate vs. gluconate), iron dose
administered, and body iron stores. For instance, 10–35% of an oral iron dose is
normally absorbed, whereas up to 80–95% of iron is absorbed in patients with iron
deficiency anemia (94).
Iron absorption is significantly reduced by the presence of phytate in the diet.
Phytates or hexaphosphates are natural components of vegetables and cereals that
bind iron in the gastrointestinal tract to form insoluble and unabsorbable com-
pounds. Ascorbic acid inhibits iron chelation to phytates and also reduces iron to
the ferrous form, making it more available for absorption (94). The amount of
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ascorbic acid needed to inhibit phytate binding to iron depends on the amount of
phytate present in the gastrointestinal tract (95,96). The greater the amount of
phytate that is present, the more ascorbic acid is required to reverse the inhibition.
With meals containing no phytates, ascorbic acid increases iron absorption by
about 60% (97). When phytates were added into wheat rolls at 2 mg, 25 mg, and
250 mg, iron absorption was inhibited by 18, 64, and 82%, respectively. When
coadministered with 50 mg of ascorbic acid, absolute iron absorption was highest
when the rolls contained no phytates, and was lowest when the rolls contained
250 mg of phytates. It is estimated that about 80 mg of ascorbic acid is needed to
counteract the effects of 25 mg of phytates, and a few hundred milligrams of
ascorbic acid are required to counteract the effects of 250 mg of phytates (98).
The average North American person consumes about 750 mg of phytates daily,
although wide individual and geographical variation exist (99).
Iron absorption was increased two- to threefold when 50 mg of ascorbic acid was
added twice daily to each meal (93–96). The first 50–100 mg doses of ascorbic acid
appear to have the most significant effects on iron absorption. Higher doses have
little additional effects (97). Administration of ascorbic acid at doses of 500 mg
twice daily after meals for 2 months significantly improved iron status in strict
vegetarians (100). However, there was no significant effect on serum ferritin levels
when higher ascorbic acid doses of 1 g twice daily were given to adults consuming a
well-balanced diet. The lack of significant response with higher ascorbic acid doses
may indicate that iron reserves are maintained under tight control regardless of the
mechanisms that enhance iron bioavailability (101). Also, ascorbic acid supple-
mentation may have little effect on improving iron absorption in well-nourished,
iron-replete subjects.
The effects of ascorbic acid on iron retention were also evaluated in a study of
premenopausal women following induction of iron depletion by a low iron diet and
phlebotomy. Women in this study consumed a low iron diet that provided 5 mg of
elemental iron per 2000 calories for 67–88 days. At the end of the low iron diet
period, subjects were divided into three groups to receive a diet containing either
13.7 mg of iron per 2000 calories, supplemental ascorbic acid 500 mg 3 times daily
with meals, or a placebo supplement for a total of 5.5 weeks. Study results showed
significant improvement in apparent iron absorption (defined as the difference
between dietary and fecal iron) with ascorbic acid supplementation compared to
placebo. Blood analysis at the end of 5 weeks showed ascorbic acid supplementation
to have also improved hemoglobin, serum iron concentration, and erythrocyte
protoporphyrins. Ascorbic acid had no effect on improving serum ferritin, trans-
ferrin saturation, hematocrit, or total iron-binding capacity (102).
The effect of ascorbic acid on iron absorption was also reported in 54 preschool
Indian children who had iron deficiency. Ascorbic acid supplemented at a dose of
100 mg twice daily given with meals for 60 days resulted in a significant improve-
ment in hemoglobin (p< 0.001) and red cell morphology as compared with placebo
(p < 0.01) (103). In another study of 65 Chinese children with mild iron deficiency
anemia who were consuming a predominantly vegetarian diet, daily ascorbic acid
supplementation at 50 mg, 100 mg, and 150 mg had similar effects on improving
iron status (104).
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The fraction of iron in ferritin and ferric hydroxide that enters the non-heme
dietary iron is also influenced by diet composition. One study compared the
absorption of iron from ferritin iron and ferric hydroxide in 35 multiparous
women. When administered in water, the geometric mean iron absorption was 0.7
and 2.4% from ferritin iron and ferric hydroxide, respectively. With the presence of
ascorbic acid 100 mg in dietary maize porridge, iron absorption increased to 12.1%
for ferritin and 10.5% for ferric hydroxide, compared to 0.4% for both compounds
with maize porridge without ascorbic acid (105).
Ascorbic acid in fruit juices and vegetables is as effective as equal amounts of
synthetic ascorbic acid in enhancing iron absorption (96). In a study that evaluated
the effect of fruit and fruit juices on iron absorption from a rice diet containing
0.4 mg of iron, juices of citrus fruits with higher ascorbic acid content resulted in
higher amounts of iron absorbed (106).
Iron supplements are commercially available in different salt forms (gluconate,
fumarate, sulfate) each providing different amounts of elemental iron (107). Iron
sulfate, the most widely prescribed oral iron supplement, is usually given in 1–3
daily doses.Most clinical evidence of enhanced iron absorption with ascorbic acid is
with iron sulfate. (94,108). Coadministration of ascorbic acid 100–200mg/daywith
iron supplements enhances iron absorption, particularly in anemic patients (94).
Patients who absorb iron poorly, such as those with gastrectomy, would most
benefit from ascorbic acid supplementation during oral iron therapy (109). Various
combinations of commercial iron and ascorbic acid formulations can be found,
such as Fero-Grad-5001 (timed release tablet containing ferrous sulfate 105 mg
with sodium ascorbate 500 mg), Vitelle Irospan1 (timed release tablet and capsule
containing ferrous sulfate exsiccated 65mgwith ascorbic acid 150mg), Hemaspan1
(containing ferrous fumarate 110 mg with ascorbic acid 200 mg), and Cevi-Fer1
(timed release capsule containing ferrous fumarate 20 mg with ascorbic acid
300 mg). Slow-release iron formulations may result in portions of the dose bypass-
ing the intestinal sites of absorption.
4. EFFECTS OF SPECIFIC NUTRIENTS ON REDUCING DRUG
TOXICITY
4.1. Folic Acid and Fluorouracil
Fluorouracil (5-FU) is a fluorinated pyrimidine antineoplastic antimetabolite
used in the palliative management of colorectal, gastric, pancreatic, breast, ovarian,
and head and neck cancers. 5-FU exerts its effects primarily through its active
metabolite fluorodeoxyuridine monophosphate that inhibits thymidylate synthase,
a key enzyme in pyrimidine synthesis. Leucovorin, a modulator of 5-FU activity, is
typically administered intravenously in combination with 5-FU to enhance 5-FU
activity. Leucovorin enhances thymidylate synthase inhibition through increasing
the intracellular pool of folates that stabilize the thymidylate synthase–fluorode-
oxyuridinemonophosphate complex (110,111). Because reduced folatemetabolites
enhance 5-FU antitumor activity, folic acid has been proposed as an alternative to
leucovorin as long as it generates the same plasma metabolite levels. Animal studies
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have shown potential modulating effects for folic acid in mice with lymphocytic
leukemia treated with 5-FU (112). However, human studies evaluating the role of
folic acid as possible modulator of 5-FU activity are limited.
A crossover, randomized pharmacokinetic study evaluated the metabolism of
folic acid and its ability to yield reduced folates. The study included 10 adult
volunteers who were divided into two groups. One group received folic acid at
doses of 25 mg/m2 and the other group received 125mg/m2. After a 2-week washout
period, the same group received the same folic acid dose by the alternative route.
Serial blood samples were collected over 24 h following folic acid administration.
Plasma samples were analyzed for folic acid and for reduced folate metabolite
concentrations. Study results showed a twofold increase in plasma reduced folate
concentrations with the higher oral folic acid dose as compared to the lower dose. In
comparison with other studies using leucovorin, the same reduced folate metab-
olites were generated following folic acid administration. Folic acid at 125 mg/m2
was at least as effective as leucovorin in increasing plasma reduced folate concen-
trations. However, folic acid metabolites accumulated at a slower rate and persisted
longer than leucovorinmetabolites. Based on these results and considering the short
half-life of 5-FU, the study concluded that folic acid offers a potential therapeutic
alternative to leucovorin in modulating 5-FU efficacy. It was also concluded that
giving folic acid 4–6 h before 5-FU allows enough time for effective accumulation of
reduced folate metabolites (113).
A clinical study combining 5-FU and high-dose folic acid yielded disappointing
results. The study included 22 patients with metastatic colorectal cancer who
received a weekly dose of 5-FU 600 mg/m2 (maximum 1 g) administered 1 h
after an intravenous folic acid dose. The starting folic acid dose was 40 mg/m2
intravenously escalated based on tolerance to the maximum dose of 140 mg/m2.
Study results showed a low response rate and severe toxicities with the combin-
ation therapy of folic acid and 5-FU, as compared to 5-FU alone. Only four
patients had partial responses for a mean duration of 4 months; no patient had a
complete response. Severe diarrhea requiring hospitalization was reported in 12
patients and also caused 3 patients to drop out of the study. Two patients
developed leukopenia and later died from sepsis. The study concluded that the
use of folic acid with 5-FU could not be justified and that further studies were still
needed. There was no clear explanation for the low response rate and high
toxicities encountered in this study. The 5-FU dose was within the usual recom-
mended dose. Mean serum folate concentrations at 1 h after folic acid adminis-
tration were 11 nmol/L higher than the in vitro optimal levels for stabilization of
the thymidylate synthase–fluorodeoxyuridine monophosphate complex. How-
ever, interpretation of these levels is difficult because serum folate levels do not
necessarily correlate with intracellular folate concentrations. Also, it was
unknown whether folic acid or the folic acid dose could have contributed to
these effects, or even if patients with colorectal cancer are more sensitive to the
combination therapy (114). For instance, severe gastrointestinal toxicities (e.g.,
stomatitis and diarrhea) are more commonly seen in patients with colorectal
cancer who are treated with leucovorin and 5-FU, as compared to 5-FU alone.
Additionally, it remains unknown whether reductase enzyme phenotype plays any
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role in the findings. The C677T genotype codes for a poorly functional MTHFR
that allows accumulation of 5,10-methylenetetrahydrofolate which increase the
thymidylate synthase effects of 5-FU and drug-induced myelosuppression (115).
For safety reasons, it is generally recommended that patients who develop gastro-
intestinal toxicity not be initiated or continued on leucovorin therapy with 5-FU
and that patients should be monitored closely until diarrhea resolves (116).
At present, intravenous leucovorin remains the agent of choice for modulation of
5-FU effect. The safety, efficacy, optimal dose, and dosing schedule for folic acid as
a modulator of 5-FU activity remain unknown. Studies comparing leucovorin to
folic acid are needed before folic acid can be recommended as a safe and effective
modulator of 5-FU effect in the treatment of cancer.
4.2. Folic Acid and Methotrexate
Methotrexate is an antineoplastic antimetabolite used for the treatment of cer-
tain cancers. It is also used for treating psoriasis and rheumatoid arthritis (RA).
Methotrexate use in RA is based on its antiinflammatory, immunosuppressive, and
antiproliferative effects. A low methotrexate dose of 5–25 mg/wk is often used for
short- and long-term treatment of adults with RA (117,118). Higher methotrexate
doses are exceptionally used when efficacy is not achieved at low doses. Significant
toxicities, especially bone marrow suppression, occur at methotrexate doses exceed-
ing 20 mg/wk (119). Dose-related hematological, gastrointestinal, hepatic, and
pulmonary toxicities frequently lead to cessation of methotrexate therapy
(120,121).
Methotrexate is structurally similar to folic acid. Methotrexate inhibits the
dihydrofolate reductase enzyme that reduces folic acid to tetrahydrofolic acid.
This results in decreased intracellular levels of reduced folates and inhibition of
deoxyribonucleic acid (DNA) synthesis and cellular replication (120,121). The
resultant folate depletion and inhibition of folate-dependent enzymes contribute
to methotrexate toxicities in nontarget tissues. Diarrhea, stomatitis, and leukopenia
are manifestations of methotrexate toxicity that mimic the symptoms of folic
acid deficiency (122). Thus, adequate folate supplementation is crucial to reduce
methotrexate toxicity.
Leucovorin (folinic acid) is a chemically active reduced folate derivative that is
used clinically as a folate rescue to counteract methotrexate toxicity. Low oral doses
of leucovorin at 2.5–5 mg/wk are used in combination with low-dose methotrexate
(123). Low leucovorin doses reduce methotrexate toxicity without altering
its efficacy. However, higher leucovorin doses (45 mg/wk) may counteract
methotrexate efficacy and result in worsening of RA (124). As such, folic acid
has been investigated as a possible substitute for leucovorin. Compared to
methotrexate, folic acid has a lower affinity to the dihydrofolate reductase enzyme.
This gives folic acid the advantage of reducing methotrexate toxicity without
counteracting its efficacy.
Low plasma and erythrocyte folate and high homocysteine levels were reported in
patients treated with methotrexate without folate supplementation (125,126). Plasma
homocysteine levels decreased following folic acid or folinic acid supplementation
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(126). Reducing homocysteine levels may have long-term cardiovascular protective
effect because hyperhomocysteinemia may be a risk factor for cardiovascular
disease (127).
The optimal dose and the timing of folic acid supplementation in relation to
methotrexate therapy are still debatable. Although weekly folic acid doses of 1 mg
(128) and 5 mg (120)were shown to reduce low-dose methotrexate toxicity, higher
doses were suggested to sufficiently preventmethotrexate toxicity (129). The effects
of folic acid on reducing low-dose methotrexate toxicity were evaluated in a double-
blind, placebo-controlled trial of 79 patients with RA. Oral folic acid doses of 1 mg/
day (5 mg/wk) or 5.5 mg/day (27.5 mg/wk) were given 5 days a week on days not
coinciding with methotrexate administration. Study results showed that either folic
acid dose resulted in lower toxicity scores compared to placebo (p< 0.001). Neither
folic acid dose interfered with methotrexate efficacy as assessed by joint indices and
grip strengths (121). However, results of another study using folic acid doses at
5 mg/day for 13 consecutive days along with weekly intramuscular methotrexate
showed alterations in methotrexate pharmacokinetics. There was a significant
decrease in plasma methotrexate concentrations and increased total methotrexate
clearance. Study investigators concluded that decreased plasma methotrexate con-
centrations were possibly due to folic acid-induced increased cellular methotrexate
uptake (130). Based on these results, the question remains about the optimal folic
acid dose that reduces methotrexate toxicity without interfering with its efficacy.
A meta-analysis of seven double-blind, randomized, controlled studies was con-
ducted to evaluate the effects of folic acid or folinic acid on the toxicity of low-dose
methotrexate (< 20 mg/wk) in patients with RA. Results of the meta-analysis
showed a 79% reduction in methotrexate-induced mucosal and gastrointestinal
toxicity with folic acid supplementation. A clinically, but not statistically, signifi-
cant 42% reduction of the same side effects was seenwith folinic acid. Similar effects
were also achieved with low- and high-dose folic acid (1–27.5 mg/wk) or folinic acid
(1–20 mg/wk). However, high folinic acid doses were associated with increased
tender and swollen joint count, a possible indication of decreased response to
methotrexate (120). The protective effects of folic acid reported in the meta-
analysis (120) were not, however, replicated in a later individual study (131). In
a 48-week, multicenter, randomized, double-blind, placebo-controlled study, folic
acid 1 mg/day and folinic acid 2.5 mg/wk reduced the incidence of elevated liver
enzymes without affecting the incidence, severity, or duration of other toxicities
including mucosal and gastrointestinal side effects (131).
Based on available data, folic acid supplementation appears to reduce low-
dose methotrexate toxicity (129) and results in less frequent interruption of
methotrexate therapy (131). Relying on dietary folic acid intake alone may not
be sufficient to prevent methotrexate toxicity (132). Because folic acid supplements
are safe, effective, and less expensive than folinic acid (133), weekly oral folic acid
supplementation given on non-methotrexate days appears an appropriate substitute
to leucovorin. Although there is no agreement on the optimal folic acid dose, clinical
studies reported weekly folic acid doses of 1 mg, 5 mg, and 27.5 mg to be safe
and effective in reducing low-dose methotrexate toxicity (120). Baseline patient
folate status, methotrexate dose, duration of methotrexate therapy, and possibly
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reductase (DHFR, MTHFR) enzyme phenotypes should play a role in determining
the optimal protective dose of folic acid. Reports of possible liver protective effects of
folic acid are encouraging and require further exploration (134).
4.3. Pyridoxine and Isoniazid
Isoniazid is an antimycobacterial agent used for the treatment and prophylaxis of
Mycobacterium tuberculosis infections. Peripheral neuropathy is the most common
side effect of isoniazid therapy (135). Peripheral neuropathy is dose-related and is
most likely to occur in slow acetylators, chronic alcoholics, and malnourished,
uremic, and diabetic patients. Signs and symptoms of peripheral neuropathy
include paresthesias of the feet and hands, muscle weakness, and diminished or
exaggerated reflexes. The mechanism of isoniazid-induced peripheral neuropathy is
likely related to isoniazid-induced pyridoxine deficiency or to isoniazid blocking the
effect of pyridoxal phosphate synthesis by inhibition of pyridoxine kinase activity
(136,137). Vitamin B6 exists in the body as pyridoxine, pyridoxal, and pyrid-
oxamine (138). Pyridoxine kinase is the enzyme that converts pyridoxal to
pyridoxal phosphate (136,137). Pyridoxal phosphate is the active byproduct of
pyridoxal metabolism that acts as a coenzyme in the metabolism of neurotransmit-
ters. Reduced pyridoxal phosphate availability during isoniazid therapy is believed
to cause a reduction in neurotransmitter synthesis (including gamma-amino butyric
acid) that eventually leads to peripheral neuropathy (137).
The incidence of peripheral neuropathy correlates with the isoniazid dose and the
presence or absence of patient-specific factors. Peripheral neuropathy occurs in
about 1–2% of patients treated with the usual isoniazid doses of 3–5 mg/kg/day
(135). The incidence of peripheral neuropathy increases to 40% with isoniazid
doses of 20 mg/kg/day (136). In malnourished patients, even low isoniazid doses of
4–6 mg/kg/day may cause peripheral neuropathy in up to 20% of patients (137).
Peripheral neuropathy does not usually appear until 6 months of isoniazid therapy
(135), but it could appear earlier in malnourished patients or those with preexisting
pyridoxine deficiency (139).
It is common practice to supplement pyridoxine at doses of 15–50mg/day, during
the course of isoniazid therapy. Higher pyridoxine doses of 100mg/day are required
in patients treated with hemodialysis. Increased pyridoxine requirements during
hemodialysis likely result from reduced pyridoxine metabolism to active pyridoxal
phosphate and increased dialysis clearance of pyridoxal phosphate (140). Pyrid-
oxine has also been used to prevent or treat isoniazid-induced psychosis (138,141)
and seizures (142,143). Seizures are the major toxic reactions of isoniazid overdose
(135). In case of isoniazid overdose, intravenous pyridoxine doses of 1 g for each 1 g
of isoniazid dose ingested were used without evidence of pyridoxine toxicity
(143,144).
In summary, peripheral neuropathy rarely occurs in well-nourished patients
treated with isoniazid doses up to 5 mg/kg/day (145). Adult patients treated with
isoniazid, especially those at high risk for peripheral neuropathy, should receive
prophylactic oral pyridoxine doses of 50 mg/day (135). Although high pyridoxine
doses can possibly reduce isoniazid activity (146) or even cause neuropathy (147),
pyridoxine doses of 100–200 mg/day have been safely used to treat isoniazid-induced
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peripheral neuropathy (137,146). The practice of avoiding pyridoxine prophylaxis in
children receiving isoniazid should be discouraged, especially in malnourished chil-
dren (148). Children treated with isoniazid may be supplemented with oral pyridox-
ine at a dose of 1–2 mg/kg/day (149).
5. EFFECTS OF SPECIFIC NUTRIENTS ON ENHANCING
DRUG EFFECT
5.1. Calcitriol and Docetaxel
Docetaxel is an antineoplastic mitotic inhibitor used in the treatment of breast,
ovarian, head and neck, nonsmall cell, and hormone refractory androgen-
independent prostate cancer (AIPC). In patients with AIPC, docetaxel-based ther-
apy in conjunctionwith other chemotherapy agents improved patient survival, bone
pain, and quality of life. The antineoplastic activity of docetaxel may be signifi-
cantly enhanced when given in combination with calcitriol (1,25-dihydroxy-vitamin
D). Calcitriol is the most biologically active form of vitamin D that exerts its
antitumor activity at supraphysiologic concentrations. At the cellular level, calci-
triol exerts its antitumor effects via a genomic pathway that is mediated by the
vitamin D receptor present in many tissues and via cytoplasmic signaling pathways
through protein kinases, lipases, and prostaglandins. Clinically, several mecha-
nisms are proposed for calcitriol antineoplastic activities that varied with tumor
and experimental models. These include induction of cell apopotosis, inhibition of
differentiation and proliferation, and reduction in angiogenesis and invasiveness. In
experimental and clinical studies, combining calcitriol with other cytotoxic agents
(e.g., paclitaxel, docetaxel, cisplatin, carboplatin, mitoxantrone, and platinum com-
pounds) has shown synergistic and/or additive antitumor effects in certain types of
cancer. When combined with glucocorticoids, calcitriol-mediated inhibition of
tumor cell growth and cycle cell arrest were also enhanced (150,151).
The antineoplastic effects of calcitriol are dose dependent and occur at concen-
trations that exceed the physiologic calcitriol range. Calcitriol concentrations
 1 nmol/L are required for in vitro antineoplastic activity. Clinically, achieving
these high calcitriol concentrations with high daily calcitriol doses resulted in
hypercalcemia, a limiting toxicity of intensive calcitriol regimen. Therefore, daily
dosing was replaced with weekly oral calcitriol administration with the goal of
avoiding hypercalcemia while still achieving high calcitriol concentrations. In a
phase I study, weekly oral calcitriol dose escalation from 0.06 mg/kg to 2.8 mg/kg
achieved higher blood calcitriol concentrations from 3.7 to 6 nmol/L without a
dose-limiting toxicity. With weekly calcitriol dosing at 60 mg, self-limited hyper-
calcemia was observed. There was no dose-limiting toxicity observed with single
calcitriol doses up to 165 mg (150).
Data are emerging on the beneficial role of a weekly high calcitriol dose in
combination with docetaxel for the treatment of patients with AIPC. Preliminary
human data also show a possible beneficial effect of a combined regimen using
calcitriol and docetaxel for improving the quality of life and pain relief of AIPC-
treated patients (152). A single center, phase II study evaluated the role of combin-
ing calcitriol and docetaxel in the treatment of 11 patients with AIPC. Oral calcitriol
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was administered weekly at 0.5 mg/kg on day 1 followed by intravenous docetaxel
36 mg/m2 on day 2 for 6 consecutive weeks of an 8-week cycle. The five patients who
completed the 8-week cycle had at least a 50% reduction in prostate-specific antigen
(PSA) (153). Another phase II study of 37 patients with AIPC used a similar dosing
regimen of calcitriol and docetaxel. The PSA response rate was 81% (30 of 37
patients); 59% of patients (22 of 37 patients) had> 75% reduction in PSA. Overall,
1-year patient survival was 89%, and treatment related toxicities were no different
than with a single dose docetaxel (154).
Because the commercial calcitriol (Rocaltrol1) formulation is available in 0.5 mg
capsules, a large number of capsules (about 70–100) is required for each weekly high
calcitriol dose. An investigational high-concentration calcitriol formulation (DN-
101) was developed to overcome this limitation. A double-blind, randomized,
international, multicenter, phase II study (Androgen Independent Prostate Cancer
Study of Calcitriol Enhancing Taxotere ¼ ASCENT-1) of 250 patients with AIPC
compared the effects of combining docetaxel with the DN-101 formulation or with
placebo. Oral DN-101 45 mg or placebo was given on day 1 before intravenous
docetaxel was administered on day 2 at weekly doses 36 mg/m2 for 3 weeks of a
4-week cycle. The primary study endpoint was a 50% reduction in PSA confirmed
4 weeks later within 6 months. The primary endpoint was reached in 59% of
DN-101-treated patients compared to 48% of placebo-treated patients (p ¼ 0.16).
At any time during the study, overall PSA response rates were 63% in DN-101-
treated patients compared to 52% in placebo-treated patients (p ¼ 0.07). An
adjusted survival analysis showed improved survival in the DN-101 group com-
pared to placebo (hazard ratio 0.67). The incidence of grade 3 and 4 adverse events
(hematologic and non-hematologic) was significantly lower in the DN-101 group
compared to placebo (58% vs. 70%, respectively; p¼ 0.065). In the DN-101 group,
there were significantly fewer serious adverse events (2.4 % vs. 9.6%; p¼ 0.02) and
thromboembolic events compared to placebo (1.6% vs. 7.2%; p ¼ 0.03). Study
investigators concluded that DN-101 treatment in combination with docetaxel does
not increase docetaxel toxicity. Although the docetaxel and DN-101 combination
improved survival of AIPC patients, this requires further confirmation in other
studies because survival was not a primary endpoint of this ASCENT-1 study
(155). Currently, a phase III study (ASCENT-2) including 900 patients with
AIPC is underway comparing weekly DN-101 with weekly docetaxel to the stand-
ard 3-weekly docetaxel 75 mg/m2 with prednisone. Results of the ASCENT-2 study
may better define the role of high-dose calcitriol in the treatment of AIPC. Calcitriol
use as adjunctive therapy for specific malignancies primarily remains investiga-
tional at this time.
5.2. Plant Stanols and Statins
The management of dyslipidemia combines drug therapy with lifestyle modifi-
cations. HMG-CoA reductase inhibitors (statins) are the most widely prescribed
agents to lower serum LDL concentration. Besides reducing saturated fat, trans fat,
and cholesterol intake, an alternate or adjunct approach in managing hypercholes-
terolemia is inhibiting cholesterol absorption with dietary inclusion of plant sterols
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and stanols. Plant sterols and stanols block dietary and biliary cholesterol absorp-
tion in the small intestines with subsequent reduction of serum cholesterol and LDL
concentrations (156,157).
Plant sterols (phytosterols) are naturally occurring plant constituents. They are
28-carbon (campesterol) and 29-carbon (sitosterol and stigmasterol) sterols found
in edible oils, nuts, and seeds. Plant stanols are saturated derivatives of plant sterols,
with sitostanol being the most common. Sitostanol is found mainly in wood pulp,
tall oil, and to a lesser extent, in soybean oil.
The Western diet provides about 100–300 mg/day of plant sterols and 20–50 mg/
day of plant stanols. Plant stanols and sterols have been incorporated into various
food products, including margarine and salad dressing. They are more commonly
used in Europe than in the United States. Although plant stanols and sterols have
been shown to be equally effective in reducing serum cholesterol concentrations
(156), the compounds have inherent differences. For instance, plant stanols are
preferable over plant sterols because they are relatively unabsorbed from the gastro-
intestinal tract. Although plant sterols are poorly absorbed, daily sterol intake of
3.24 g increases serum sitosterol and campesterol by 40 and 70%, respectively.
Because of concerns that plant sterols and their byproducts may initiate the devel-
opment of atherosclerosis, plant stanols appear safer substances, especially during
long-term consumption (158).
Plant stanols have been used as adjunctive therapy with statins to manage hyper-
cholesterolemia. Because statins inhibit cholesterol synthesis and stanols block
cholesterol absorption, an additive effect of combining the two agents would be
anticipated to further lower serum cholesterol concentrations. The combined effects
of statins and plant stanols are equivalent to a one- to twofold increase in statin dose
(159). A double-blind, placebo-controlled study evaluated the effects of adding
dietary plant stanol esters (esterified plant stanols) to statin therapy (160). One-
hundred-sixty-seven adults with serum LDL cholesterol concentrations  130 mg/
dL and total cholesterol concentrations  350 mg/dL who had been receiving a
stable dose of a statin for at least 90 days were included in the study. Subjects were
randomized to receive either dietary canola oil-based spread in three servings that
provided 5.1 g/day of plant stanol ester (equivalent to 3 g/day of plant stanols) or
placebo for a period of 8 weeks. Study results showed plant stanols in combination
with statins significantly reduced serum total cholesterol (12% vs. 5%, p < 0.0001)
and LDL concentrations (17% vs. 7%, p < 0.0001) compared to placebo. There
were no changes in serum triglyceride or HDL concentrations. Plant stanols were
well tolerated (160).
Plant sterols have also been studied. A double-blind, randomized, multicenter
study evaluated the effects of plant sterol ester margarine on serumLDL cholesterol
concentrations when combined with a statin drug in subjects with hypercholester-
olemia (baseline LDL cholesterol  97 mg/dL) (161). The study design used four
parallel treatment arms with four daily treatment options of placebo with regular
margarine 25 g (n¼ 38), placebo with sterol ester margarine 25 g (2 g of plant sterol;
n ¼ 39), cerivastatin 0.4 mg with regular margarine 25 g (n ¼ 38), and cerivastatin
0.4 mg with sterol ester margarine 25 g (n ¼ 37). Study results at the end of 4 weeks
showed that cerivastatin significantly reduced serum LDL cholesterol by 32%
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compared to placebo (p< 0.0001). Sterol ester margarine reduced serum LDL
cholesterol concentrations by 8% compared to regular margarine (p< 0.0001).
There was an additive effect of sterol ester margarine with cerivastatin that resulted
in a 39% reduction in serum LDL cholesterol concentrations. All treatments were
well tolerated. Study investigators concluded that adding sterol ester margarine to
statin therapy reduces serum LDL cholesterol that is equivalent to doubling the
statin dose (161).
The effects of plant sterols were also investigated in patients with familial hyper-
cholesterolemia. Patients with heterozygous familial hypercholesterolemia have
markedly elevated serum cholesterol concentrations and require lifelong intensive
dietary and lifestyle modifications with intensive lipid-lowering drug therapy for
hypercholesterolemia. A double-blind, randomized, placebo-controlled, crossover
study with two consecutive periods of 8 weeks compared the effects of plant sterol
intake at 2.5 g/day in fat spread to placebo on plasma lipid and lipoprotein
concentrations (162). Thirty patients with heterozygous familial hypercholester-
olemia were concurrently treated with a statin drug, and 32 patients with type IIa
primary hypercholesterolemia with total serum cholesterol concentrations
> 250 mg/dL were not being treated with lipid-lowering agents. Because of possible
carryover effects at the end of the two 8-week study periods, data analysis was
limited to the first phase of treatment. At the end of the first 8 weeks, serum LDL
cholesterol concentrations had significantly decreased by 10% with sterol treatment
compared to no decrease in the placebo group (p< 0.0001). There was no difference
in response between patients receiving or not receiving concomitant statin therapy
(162). The lack of combined effects between plant stanols and sterols with statins in
patients with heterozygous familial hypercholesterolemia was replicated in another
study of children with heterozygous familial hypercholesterolemia. Combined inhib-
ition of cholesterol absorption by plant stanol ester intake at 2 g/day and inhibition
of cholesterol synthesis with pravastatin therapy (40 mg/day) in these patients did
not significantly improve serum cholesterol concentrations, especially in patients
with the highest serum cholesterol concentrations (163). It was postulated that high
baseline serum cholesterol concentrations, possible enhanced cholesterol absorption
by statins as detected by increased cholesterol absorption markers, and reduced
biliary secretion of plant sterols may be contributing factors to the lack of significant
combined effects between plant stanol esters and statins in patients with heterozy-
gous familial hypercholesterolemia (163).
Maximum lowering of serum LDL concentrations appears to be achieved with
plant stanol esters at 2 g/day; higher doses are unlikely to provide additional
efficacy (164). When considering statin therapy alone or in combination with
stanols, doubling the statin dose would reduce serum LDL concentrations by an
additional 6%, whereas a 10% reduction in LDL concentrations is achieved when
statins are combined with stanols. Also, doubling the statin dose carries the risk of
hepatic and muscle toxicity. Therefore, adding plant stanols to statin therapy
appears a safer alternative (159,160,164). A possible limiting factor to stanol
efficacy alone is related to liver upregulation of its LDL receptor activity to increase
LDL synthesis in response to decreased cholesterol levels in liver cells (165). The
magnitude of this compensatory effect remains unknown.
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Because plant sterols are not water-soluble but dissolve better in fat, most clinical
studies of sterol-containing foods have been brands of stanol-enriched margarine.
However, patients with hypercholesterolemia commonly avoid using margarine
products to limit their fat intake, and using stanol-containing margarine is not
convenient when eating out at a restaurant. A placebo-controlled study evaluated
the effect of a daily dispersible tablet formulation containing a 1.8 g dose of soy
stanols on serum LDL cholesterol in 26 subjects who were already eating a heart-
healthy diet and taking statin drugs. To help them dissolve in water and get to their
targets in the intestines, stanols were combined with lecithin and compressed
into the investigational tablet formulation. Following 9 weeks of therapy, study
results showed that the addition of plant stanols in a tablet decreased serum LDL
cholesterol concentrations by an additional 9.1% and serum total cholesterol by
12.2 mg/dL (166).
Currently, a commercial product of plant stanol esters (Benecol1) is available
in spreads (regular and light) and Chews. Benecol1spread is taken with meals in
2–3 daily servings (1 serving ¼ 1 tablespoon ¼ 0.85 g of plant stanol esters).
Benecol1Chews are usually taken as two Chews twice daily with meals and snacks
(1 Chew ¼ 0.85 g of plant stanol esters). There are also several multi-ingredient
products available as nutritional supplements that contain plant stanols and sterols.
However, the exact quantities of ingredients in these products are less well defined.
The overall efficacy of plant stanols and sterols on lowering serum cholesterol
remains modest, especially with the associated compensatory increase in liver
cholesterol synthesis (165). Also, stanol-enriched diets do not appear to have any
significant effects on lowering serum triglyceride concentrations (167).
The relatively high cost of plant stanol and sterol products and the need to
consume them several times daily make them less appealing to the consumer.
However, data are emerging on the cost-effectiveness of dietary supplementation
of plant stanol and sterols. A European study evaluated the cost-effectiveness in
Euros per quality adjusted life years (E/QALY) of the daily intake of dietary plant
stanol ester spread in combination with and without statin drugs in preventing
coronary heart disease (CHD). This was based on conducting two meta-analyses of
randomized, placebo-controlled clinical studies: one meta-analysis evaluated the
reduction of total serum cholesterol concentrations with the use of stanol esters
alone and another meta-analysis evaluated reduction of total serum cholesterol
concentrations with the use of stanol ester spread in combination with statin
therapy. Health-care data from Finland were used to determine age- and gender-
specific CHD risk factors. Study results showed that regular use of plant stanol ester
spreads alone (assuming consumption of 2 g stanol/day) and in combination with
statins reduced serum total cholesterol concentrations by about 14 mg/dL and
15 mg/dL, respectively. Regular use of plant stanol ester spreads was found to be
cost-effective in preventing CHD in adult males and older age women with total
serum cholesterol concentrations  194 mg/dL. Based on the assumption that
changes in serum cholesterol concentrations are converted to changes in the inci-
dence of CHD events using the CHD risk equations, the base case cost (E/QALY)
gained ranged from E7,436 to E20,999 in men and from E34,327 to E112,151 in
women (168).
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6. CONCLUSIONS
6.1. Limitations of Current Data
Data on clinically beneficial drug–nutrient and drug–food interactions are
scarce. Well-designed clinical studies of positive drug–nutrient interactions are
few, andmainly focused on certain drugs and nutrients. A limitation to the available
data on beneficial drug–food and drug–nutrient interactions is that many studies
were performed in healthy individuals and/or with small sample size populations.
Because disease states may alter the normal physiology of organ functions that
ultimately affect drug and nutrient disposition, data from healthy subjects may not
always be replicated in sick individuals.
6.2. Research Needs
The list of commonly recognized positive drug–nutrient and drug–food inter-
actions that optimize drug effects is limited, considering the extensive number of
drugs available and their potential interactions with various nutrients and foods.
Future avenues should include research that focuses on identifying the potential
benefits of nutrients that enhance therapeutic drug effect and prevent drug toxicity,
determining the populations that may benefit from these positive interactions, and
defining the appropriate nutrient intake and drug dosing to achieve the clinically
desired beneficial effects. Prospective randomized controlled studies in patients
with different disease states and consuming different nutrients are needed to further
explore the arena of clinically beneficial drug–nutrient interactions.
6.3. Clinical Recommendations
Drug–nutrient and drug–food interactions can cause increased or decreased drug
effects. Beneficial drug–nutrient and drug–food interactions can enhance thera-
peutic drug effect and reduce or prevent drug toxicity. Clinicians should be aware
of these positive drug–nutrient and drug–food interactions and should apply them
to patient-specific clinical conditions when clinically indicated. Clinicians should
also counsel patients about the appropriate nutrient or food intake to improve the
safety and efficacy of drug therapy.
DISCUSSION POINTS
Drug–nutrient and drug–food interactions are often the result of physical and
chemical interactions between drugs and nutrients.
 Discuss the factors that can influence drug–nutrient and drug–food interactions.
 Discuss the mechanisms of positive drug–nutrient and drug–food interactions.
Positive drug–nutrient interactions can improve serum drug concentrations,
enhance therapeutic drug effects, or reduce or prevent adverse drug events.
 Discuss which nutrients can have a positive influence on drug effects.
 Discuss how nutrients can reduce drug toxicity.
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Certain foods can enhance the absorption of certain drugs.
 Discuss how a fatty meal can affect the absorption of certain drugs to enhance
their therapeutic effect.
Several of the antiretroviral drugs should be administered with food.
 Discuss the advantages of administering these antiretroviral drugs with food.
Plant stanols and sterols have been used in patients with hypercholesterolemia.
 Discuss the differences, including advantages and disadvantages, of plant stanols
vs. plant sterols for the management of hypercholesterolemia.
 Discuss the rationale behind using plant stanols in combination with statin
therapy.
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